Journal article
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically
E Munkhbaatar, M Dietzen, D Agrawal, M Anton, M Jesinghaus, M Boxberg, N Pfarr, P Bidola, S Uhrig, U Höckendorf, AL Meinhardt, A Wahida, I Heid, R Braren, R Mishra, A Warth, T Muley, PSP Poh, X Wang, S Fröhling Show all
Nature Communications | NATURE PORTFOLIO | Published : 2020
Abstract
Evasion of programmed cell death represents a critical form of oncogene addiction in cancer cells. Understanding the molecular mechanisms underpinning cancer cell survival despite the oncogenic stress could provide a molecular basis for potential therapeutic interventions. Here we explore the role of pro-survival genes in cancer cell integrity during clonal evolution in non-small cell lung cancer (NSCLC). We identify gains of MCL-1 at high frequency in multiple independent NSCLC cohorts, occurring both clonally and subclonally. Clonal loss of functional TP53 is significantly associated with subclonal gains of MCL-1. In mice, tumour progression is delayed upon pharmacologic or genetic inhibit..
View full abstractGrants
Awarded by Rosetrees Trust
Funding Acknowledgements
Open Access funding provided by Projekt DEAL.